Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia

Abstract

Earlier studies have shown the effect of laser treatment on epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). At the present time, only very few prospective trials have been performed, and many studies are based on patients' subjective assessment of the severity of epistaxis. This prospective study measures the objective effect of laser treatment in HHT patients with mild to moderate epistaxis. We introduce an objective measure to assess the severity of epistaxis: the bleeding time (BT). Before and after treatment, the quality of life, as measured by the patient, was assessed and compared to normative data. In 30 patients, we measured the BT before laser treatment 1.5 and 6.5months after treatment. The Short form 36 (SF-36), a validated health questionnaire, was completed before and 6.5months after treatment. Compared to preoperative value, BT was significantly reduced 1.5 and 6.5months after laser treatment (p<0.05) in both cases. No significant difference in quality of life, before and after treatment, was found. The quality of life of the HHT patients was reduced in five out of eight dimensions when compared with the Danish background population. Laser treatment reduces epistaxis in HHT patients with mild to moderate epistaxis for at least 6months; this group of patients have reduced quality of life compared to the background population.